Pricing Log in Create free account

InflaRx N.V. (IFRX) vs Cartesian Therapeutics, Inc. (RNAC)

InflaRx N.V. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Cartesian Therapeutics, Inc. is the larger, with a market value of $229.7M against $192.3M — 1.2× the size. InflaRx N.V. grew revenue faster over the last twelve months: −83.4% against −94.8%. Across the 13 metrics below, Cartesian Therapeutics, Inc. leads on 8 and InflaRx N.V. on 5.

Valuation

Metric IFRX RNAC Biotechnology median
P/E n/m n/m 10.60
P/S 6,308.89 125.01 9.40
P/B 1.16 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1,845.43 77.39 9.02
Earnings yield (29.70%) (78.75%) (32.88%)
Free cash flow yield (10.67%) (35.43%) (23.13%)

Profitability

Metric IFRX RNAC Biotechnology median
Gross margin (26,762.42%) 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (30.98%) 236.88% (51.96%)
Return on assets (25.90%) (42.77%) (46.06%)
Return on invested capital (87.31%) 0.00% 0.00%

Growth

Metric IFRX RNAC Biotechnology median
Revenue growth (TTM) (83.39%) (94.81%) 6.76%
EPS growth (last fiscal year) 9.41% (11.80%) 29.88%
Revenue growth, 5-year CAGR — (29.96%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IFRX RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 7.26 7.48 4.97
Net debt to EBITDA 0.97 0.89 1.01

Dividend

Metric IFRX RNAC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IFRX RNAC Biotechnology median
Market cap 192.32m 229.69m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack